10-Q: Chicago Atlantic BDC Reports Q1 2026 Results

Chicago Atlantic BDC, Inc. reported its financial results for the first quarter ended March 31, 2026, showing growth in its investment portfolio and increased investment income.

Summary

• Chicago Atlantic BDC, Inc. (LIEN) reported its financial results for the first quarter ended March 31, 2026.
• Total investment income increased to $16.7 million from $11.9 million in the prior year's quarter.
• Net investment income was $10.0 million, or $0.44 per share, an increase from $7.6 million, or $0.34 per share, in the first quarter of 2025.
• The fair value of the investment portfolio grew to $364.0 million from $333.3 million at the end of 2025.
• The company had $54.5 million in outstanding borrowings under its revolving line of credit as of March 31, 2026, with $45.5 million available.
• The company's portfolio is heavily concentrated in the cannabis industry, representing 76.4% of its fair value.
• The company's common stock traded at a discount to its net asset value per share.
• The company declared a quarterly dividend of $0.34 per share, payable in July 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, with growth in investment income and portfolio value offset by the significant discount to NAV and inherent risks in the cannabis sector.

Positives

• Investment income increased by approximately 40% year-over-year, reaching $16.7 million.
• Net investment income grew by 30% year-over-year to $10.0 million.
• The fair value of the investment portfolio increased by 9.2% from the end of the previous year to $364.0 million.
• The company's revolving line of credit provides significant available borrowing capacity ($45.5 million) to support future investments.
• No loans were on non-accrual status as of March 31, 2026, indicating good credit quality within the portfolio.
• The company's asset coverage ratio of 658% is well above the regulatory minimum of 150%.

Negatives

• The company's common stock is trading at a significant discount to its net asset value per share (31.96% as of May 13, 2026).
• The portfolio is heavily concentrated in the cannabis industry (76.4%), which carries inherent risks.
• The company's investments are primarily categorized as Level 3 assets, indicating significant reliance on unobservable inputs for valuation and inherent uncertainty.
• The company has a substantial amount of debt outstanding ($54.5 million on its revolving line of credit).

Risks

• The cannabis industry is highly speculative and faces significant legal and regulatory risks at the federal level in the U.S.
• Changes in U.S. federal policy or enforcement regarding cannabis could negatively impact portfolio companies.
• Assets collateralizing loans to cannabis businesses may be subject to forfeiture by the U.S. federal government.
• Many national and regional banks are hesitant to do business with cannabis companies, potentially limiting access to traditional banking services.
• The company's investments are primarily in floating-rate debt, making it sensitive to interest rate fluctuations.
• The company's focus on the cannabis industry exposes it to greater price volatility and risk of loss compared to more diversified funds.
• The rescheduling of medical cannabis by the DEA may introduce operational complexities and potential competition, impacting lending spreads.
• The company's common stock trading at a discount to NAV could impair its ability to raise additional capital.

Future Outlook

The company's investment objective is to maximize risk-adjusted returns on equity. It aims to achieve this by investing primarily in secured debt, unsecured debt, equity warrants, and direct equity investments in privately held businesses, often within the cannabis ecosystem. The company expects its secured loans to be secured by various assets of its borrowers and to have terms of two to six years. The company has an active pipeline of investments and is currently reviewing approximately $810.4 million of potential investments.

Management Comments

• The company believes its ability to leverage the existing investment management platform of Chicago Atlantic enables it to operate more efficiently and with lower overhead costs than other funds of comparable size.
• The company intends to pay quarterly distributions to its stockholders out of assets legally available for distribution, determined by the Board based on earnings, financial condition, and tax treatment as a RIC.
• The company's common stock has traded at prices both above and below its net asset value per share, and it is not possible to predict future trading prices relative to NAV.

Industry Context

StockSavvy.ai notes that Chicago Atlantic BDC's focus on the cannabis industry, while potentially offering high returns, also exposes it to significant regulatory and market risks. The recent DEA rescheduling of certain cannabis products could impact the industry landscape, potentially increasing competition and affecting lending spreads. The company's heavy reliance on Level 3 valuations highlights the subjective nature of its asset pricing.

Legal Proceedings

• No material legal matters or litigation were pending as of March 31, 2026.

Related Party Transactions

• The company incurred management fees of $1.53 million and income-based incentive fees of $2.46 million for the quarter ended March 31, 2026, payable to its investment adviser.
• The company has a loan administrator, Chicago Atlantic Admin, LLC, a wholly-owned subsidiary of Chicago Atlantic Group, LP, which is an affiliate.
• The Adviser, Chicago Atlantic BDC Advisers, LLC, holds approximately 2.9 million shares of the company's common stock as of March 31, 2026, representing approximately 14% of the voting stock.

Stakeholder Impact

• Shareholders may experience continued volatility due to the company's focus on the cannabis industry and the stock trading at a discount to NAV.
• The company's ability to raise capital may be impacted by the stock's discount to NAV.
• Portfolio companies may benefit from the DEA's rescheduling of medical cannabis, potentially improving their after-tax cash flows and liquidity.

Next Steps

• Continue to monitor the impact of the DEA's rescheduling of cannabis on portfolio companies and the broader industry.
• Evaluate the effectiveness of the company's investment strategy in the current market environment.
• Monitor the company's stock performance relative to its net asset value.
• The company has a registration statement filed for a potential $500 million offering of securities.

Key Dates

Recommendation

While the company shows growth in investment income and portfolio value, the significant discount to Net Asset Value (NAV) and the inherent risks associated with its heavy concentration in the cannabis industry warrant a cautious approach. The potential for increased competition and regulatory complexities following the DEA's rescheduling of cannabis also present uncertainties. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor the company's performance and the evolving industry landscape.

Keywords

Chicago Atlantic BDC, LIEN, BDC, Business Development Company, Cannabis Investment, SEC Filing, 10-Q, Quarterly Report, Debt Investments, Senior Secured Loans, Fair Value, Net Asset Value